

1 *Original Research*

2 **TITLE**

3 Large-scale cross-sectional seroepidemiologic study of COVID-19 in Japan: Acquisition of herd
4 immunity and the vaccines' efficacy

5

6 **Authors**

7 Zhenxiao Ren¹, Mitsuhiro Nishimura, PhD^{1†}, Lidya Handayani Tjan, MD, PhD¹, Koichi Furukawa,
8 MD¹, Yukiya Kurahashi, MD¹, Silvia Sutandhio, MD¹, Kaito Aoki¹, Natsumi Hasegawa¹, Jun Ariei,
9 DVM, PhD¹, Kenichi Uto², Keiji Matsui, PhD², Itsuko Sato², Jun Saegusa, MD, PhD², Nonoka
10 Godai^{3,4}, Kohei Takeshita, PhD⁴, Masaki Yamamoto, PhD^{3,4}, Tatsuya Nagashima, MD, PhD⁵, Yasuko
11 Mori, MD, PhD^{1*}

12

13 ¹Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of
14 Medicine, Kobe, Hyogo, Japan

15 ²Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan

16 ³Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life Science,
17 University of Hyogo, Hyogo, Japan

18 ⁴Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN
19 SPring-8 Center, Hyogo, Japan

20 ⁵Hyogo Prefecture Health Promotion Association, Kobe, Hyogo, Japan

21 ***Corresponding author:** Prof. Yasuko Mori, Division of Clinical Virology, Center for Infectious
22 Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo
23 650-0017, Japan. Email: ymori@med.kobe-u.ac.jp

24 Tel: +81-78-382-6272 Fax: +81-78-382-6879

25

26 †**Alternate author:** Dr. Mitsuhiro Nishimura, Division of Clinical Virology, Center for Infectious
27 Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo
28 650-0017, Japan. Email: mnishimu@med.kobe-u.ac.jp
29 Tel: +81-78-382-6272 Fax: +81-78-382-6879

30

31 **Keywords (5 items)**

32 COVID-19, SARS-CoV-2, seroepidemiologic study, vaccine, VOC

33

34 **Running title (<40 letters)**

35 Serosurveillance of COVID-19 in Japan

36

37 **Summary (<40 words)**

38 Seroepidemiologic study of COVID-19 on December 2021 in Japan showed neutralizing antibodies
39 for Delta were 78.7%, indicating the acquisition of herd immunity by mass vaccination leading to
40 convergence while those for Omicron were only 36.6%, indicating need of booster vaccination.

41

42 **ABSTRACT**

43 **Background:** The COVID-19 pandemic situation has been changing drastically worldwide due to the
44 continuous appearance of SARS-CoV-2 variants and the roll-out of mass vaccination. Periodic
45 cross-sectional studies during the surge of COVID-19 cases is essential to elucidate the pandemic
46 situation.

47 **Methods:** Sera of 1,000 individuals who underwent a health check-up in Hyogo Prefecture Health
48 Promotion Association clinics in Japan were collected in August and December 2021. Antibodies
49 against SARS-CoV-2 N and S antigens were detected in the sera by an electrochemiluminescence
50 immunoassay (ECLIA) and an enzyme-linked immunosorbent assay (ELISA), respectively. The sera's

51 neutralization activities for the conventional SARS-CoV-2 (D614G), Delta, and Omicron variants were
52 measured.

53 **Results:** The seropositive rates for the antibody against N antigen were 2.1% and 3.9% in August and
54 December 2021 respectively, demonstrating a Delta variant endemic during that time; the actual
55 infection rate was approximately twofold higher than the rate estimated based on the polymerase chain
56 reaction (PCR)-based diagnosis. The anti-S seropositive rate was 38.7% in August and it reached
57 90.8% in December, in concordance with the vaccination rate in Japan. In the December cohort, 78.7%
58 of the sera showed neutralizing activity against the Delta variant, whereas that against the Omicron was
59 much lower at 36.6%.

60 **Conclusions:** These analyses revealed that herd immunity against SARS-CoV-2 including the Delta
61 variant was established in December 2021, leading to convergence of the variants. The low
62 neutralizing activity against the Omicron variant suggests the need for the further promotion of the
63 prompt three-dose vaccination to overcome this variant's imminent 6th wave in Japan.

64

65 INTRODUCTION

66 Several turning points have occurred since the COVID-19 pandemic's emergence in December
67 2019, and the pandemic has undergone drastic changes with its progress. One of the most important
68 factors is the appearance of the continuous SARS-CoV-2 variants replacing the original variant. In
69 Japan, the Alpha variant (B.1.1.7) replaced the existing strain by around April 2021; the Delta variant
70 (B.1.617.2) then began spreading rapidly throughout the country from July to August 2021(it was
71 called the 5th wave in Japan, Suppl. Fig. S1) [1-3]. The Omicron variant (B.1.1.529) was first reported
72 in South Africa in November 2021 [4] and has spread worldwide [5] including UK and U.S. (new
73 Omicron infections: >200,000/day in the UK [6] and >1,000,000 Omicron cases per day in the U.S.
74 [7]), and it was expected to invade Japan at the end of 2021.

75 The other critical event in the pandemic has been the launch of COVID-19 vaccines. The
76 accelerated development of several vaccine platforms was based on the components of the original
77 SARS-CoV-2 strain as the template, and these vaccines have been demonstrated to be effective for
78 reducing the COVID-19 outbreak [8, 9]. The BNT162b2 mRNA vaccine (Comirnaty[®],
79 BioNTech-Pfizer, Mainz, Germany/New York, USA) [10] was approved first in Japan and
80 administered to healthcare workers starting in February 2021, then to individuals aged ≥ 65 old
81 beginning in April 2021, expanding to other populations from May 2021. The mRNA vaccines
82 developed by Moderna [11] were also approved in Japan and have been widely used since May 2021.
83 The number of vaccinated individuals in Japan is increasing rapidly, as monitored by the government
84 system [12]; as of December 2021, approx. 74% of the population has received two doses of a vaccine.
85 A three-dose vaccination policy for medical staff was initiated in December 2021 [13].

86 Periodic seroepidemiologic surveillance is useful to help determine the precise COVID-19
87 situation [14-18]. We have periodically conducted seroepidemiologic surveillance in one of Japan's 47
88 prefectures; i.e., Hyogo prefecture (population 5.4 million) located in the southern-central region of
89 Japan [19, 20]. Our previous seroepidemiologic surveillance conducted in October 2020 revealed that

90 0.15% of 10,377 sera had neutralizing activity against SARS-CoV-2 infection[20].

91 In the present study, we conducted seroepidemiologic surveys of COVID-19 in Hyogo
92 prefecture in August and December 2021, which respectively correspond to the beginning and the end
93 of the pandemic's 5th wave in Japan. We observed that the antibody positivity rate for the N antigen of
94 SARS-CoV-2 increased to 2.1% and 3.9% in those surveys, respectively, indicating the infectious rate
95 of the 5th wave.

96

97 **MATERIALS AND METHODS**

98 **Serum samples for seroepidemiologic analysis**

99 The serum samples were collected from individuals who underwent a health check-up at the
100 clinics of Hyogo Prefecture Health Promotion Association, Kobe, Japan. The 1,000 sera collected
101 during the period from July 19 to August 6, 2021 are referred to herein as the August 2021 cohort. The
102 1,000 sera collected during the period from November 22 to December 8, 2021 are referred to as the
103 December 2021 cohort. No prior information about the individuals from who the sera was collected is
104 described in this study (e.g., vaccination status and SARS-CoV-2 infection history).

105

106 **Detection of anti-Spike antibodies by ELISA**

107 Anti-Spike antibodies in the human sera were detected by an anti-S enzyme-linked
108 immunosorbent assay (ELISA) as described in our previous study (manuscript submitted). Briefly,
109 each well of a 96-well ELISA plate (Corning, New York, NY) was coated with 100 ng of Spike protein
110 dissolved in a 100 mM carbonate buffer (pH 9.0) and left at 4°C overnight. After a wash with
111 phosphate-buffered saline (PBS) containing 0.1% Tween 20 (PBST), PBST supplemented with 1%
112 bovine serum albumin was added as a blocking buffer, followed by incubation at 4°C for 2 hr. Each
113 serum serially diluted from 1:40 to 1:5120 in the blocking buffer were added to the plate and then
114 incubated at 37°C for 1 hr.

115 After a wash with PBST, goat anti-human IgG with conjugated horseradish peroxidase (abcam,
116 Cambridge, MA) diluted 1:10000 with PBST was added, followed by incubation at 37°C for 1 hr. After
117 a wash with PBST, ABTS solution (Roche Diagnostics, Indianapolis, IN) was added, and the plate was
118 incubated at room temperature for 40 min in the dark. The reaction was stopped by adding 100 µl of
119 1.5% (w/v) oxalic acid dehydrate solution.

120 The optical density at wavelength 405 nm (OD₄₀₅) was measured using the plate reader
121 Multiskan FC (Thermofisher Scientific, Waltham, MA). We set a cut-off value of 0.3 for the 1:40
122 dilution to define anti-S positivity according to the values for native sera according to our validation
123 (manuscript submitted). The value of the area under the curve (AUC) was used to evaluate the anti-S
124 antibody titer [21, 22]. The AUCs were calculated for the plot of OD₄₀₅ values according to dilution
125 factors, and an arbitrary value of 1 was given as the width for a twofold dilution step.

126

127 **Detection of anti-N antibody by ECLIA**

128 An electrochemiluminescence immunoassay (ECLIA) was conducted using the cobas e801
129 module (Roche Diagnostics, Rotkreuz, Switzerland) as in our previous study [20]. The Elecsys
130 Anti-SARS-CoV-2 assay kit (Roche Diagnostics) was used for the detection of antibodies against the
131 SARS-CoV-2 nucleocapsid (N). The measurement of anti-N antibody was performed according to the
132 manufacturer's instructions, and samples with a cut-off index (COI) >1.0 were diagnosed as positive.

133

134 **Viruses**

135 The SARS-CoV-2 Biken-2 (B2) strain, which contains the Spike D614G mutation (here called
136 D614G) was provided by BIKEN Innovative Vaccine Research Alliance Laboratories (Osaka, Japan).
137 The whole genome sequence of the B2 strain has been deposited in the DNA Data Bank of Japan
138 (DDBJ) with the accession number LC644163. The SARS-CoV-2 B.1.167.2 Delta variant (GISAID
139 ID: EPI_ISL_2158617) and the B.1.1.529 Omicron variant (GISAID ID: EPI_ISL_7418017) were

140 provided by Japan's National Institute of Infectious Disease.

141

142 **Neutralization assay**

143 The neutralization activity was measured as described [19, 20, 23] using authentic viruses. The
144 use of SARS-CoV-2 viruses was restricted to the BSL3 Laboratory at the Kobe University.

145

146 **Statistical analysis**

147 The Kruskal-Wallis test, Dunn's multiple comparison test, and Mann-Whitney U-test were
148 performed by GraphPad Prism 8 (GraphPad Software, San Diego, CA). In all statistical tests,
149 P -values ≤ 0.05 were considered significant.

150

151 **Ethics statement**

152 The seroepidemiologic surveillance was approved by the Ethics Committee of Kobe University
153 Graduate School of Medicine (approval code: B2156702). The Hyogo Prefecture Health Promotion
154 Association was also granted approval for study participation under the same Ethics Committee.
155 Information about this retrospective observational study was published on the website of Kobe
156 University Hospital, along with the opportunity to opt out.

157

158 **RESULTS**

159 **Large-scale seroepidemiologic surveillance of the anti-N positive rate**

160 The results of our large-scale seroepidemiologic surveillance in Hyogo prefecture, Japan
161 performed in August 2021 and December 2021 are as follows. As many as 1,000 samples in each
162 cohort were collected from individuals who underwent a health check-up at Hyogo Prefecture Health
163 Promotion Association clinics, with no prior information about the individuals' SARS-CoV-2 infection
164 and vaccination history. The demographic data are summarized in Table 1, and the age distributions are

165 depicted in the left panels of Figures 1A and 1B for the August 2021 and December 2021 cohorts,
166 respectively. These cohorts were composed mainly of persons of 20–69 years old with a smaller
167 number of persons aged 70–80, with few individuals <20 years old and no subjects aged <18 years
168 old.

169 The SARS-CoV-2 anti-N antibodies which show past infection by SARS-CoV-2 were detected
170 by the ECLIA [20, 24], and 21 of the 1,000 samples (2.1%) in the August 2021 cohort were deemed
171 positive given the cut-off of 1.0, whereas 39 of the 1,000 samples (3.9%) in the December 2021 cohort
172 were positive (Table 2). The age distribution of positive cases is summarized in Table 2 and illustrated
173 in the middle panels of Figure 1A,B for the August and December 2021 cohorts, respectively. In the
174 August 2021 cohort, the anti-N positive rate for the age groups 30–39 and 40–49 were relatively high at
175 3.4% (6/179) and 4.1% (10/243), respectively, and no positive cases were observed for the age groups
176 18–19 and 70–83 years (Fig. 1A, middle panel).

177 Notably, the December 2021 cohort exhibited the noticeable positive rate 10.6% (11/104) for the
178 age group 20–29 (Fig. 1B, middle panel). In contrast to the August 2021 cohort, the oldest age group
179 (i.e., 70–79 yrs) of the December 2021 cohort showed the positive rate 5.0% (2/40). The positive rate
180 for age groups 30–39 and 40–49 were not largely changed at 3.4% (5/149) and 4.7% (12/257),
181 respectively. These results demonstrate that the infection of the younger (20–29 yrs) and older (70–79
182 yrs) groups increased during the pandemic's 5th wave.

183

184 **Large-scale seroepidemiologic surveillance of the anti-S positive rate**

185 The anti-S antibodies of the August and December cohorts were analyzed by the anti-S ELISA,
186 which included the vaccination and/or infection history. With the cut-off of 0.3 for the 40-fold serum
187 dilution, the positivity rates were 38.7% (387/1,000 sera) and 90.8% (908/1,000 sera) in the August
188 and the December cohorts, respectively (Table 2). The age distribution of anti-S-positive cases is
189 summarized in Table 2 and shown in the right panels of Figures 1A and B. In the August cohort, the

190 anti-S positive rates for the age groups 60–69 and 70–83 were relatively high at 70.7% (123/174) and
191 90.2% (37/41), respectively (Fig. 1A, right panel). The December cohort demonstrated a flattened
192 positive rate at a high level (87.2%–100%) across all of the age groups tested (Fig. 1B, right panel).

193 As expected, all of the anti-N-positive sera were also anti-S-positive, with one exception for the
194 August cohort and another for the December cohort.

195

196 **Quantitative analysis of the anti-S antibody in the two cohorts**

197 We quantitatively analyzed the anti-S positive sera in the August 2021 and December 2021
198 cohorts to estimate and compare the cohorts' anti-S antibody levels. The quantitative distributions of
199 the anti-S antibody titer are shown in Figure 2A. The August 2021 cohort's distribution showed a
200 significantly higher level of AUCs with the median 13.8 compared to that of the December 2021
201 cohort with the median 8.8 (Mann-Whitney U-test).

202 We further analyzed the distributions of the anti-S antibody titer by separating the age groups
203 (Fig. 2B). There was no significant difference in the distribution among age groups in the August
204 cohort by the Kruskal-Wallis test, whereas the distribution in the December cohort showed significant
205 differences among the age groups, showing a clear tendency of decreased anti-S antibody levels in
206 the older age group (70–79), indicating that the lower anti-S antibody titer did affect infection.

207

208 **Neutralization activity of the anti-S-positive sera from the August 2021 cohort**

209 The neutralization antibody titers of the anti-S-positive subset (n=387) from the August 2021
210 cohort were quantitatively evaluated. Figure 3A depicts the distributions of neutralization antibody
211 titers against D614G and the Delta variant. Although the distributions appeared similar with the same
212 median value, i.e., 8, the Mann-Whitney U-test result indicated that the neutralizing titers for D614G
213 were significantly higher than those for the Delta variant. The neutralization positivity rate in the
214 anti-S-positive subset also showed a similar result in that there were slightly higher rates for D614G

215 and Delta at 85.5% and 77.3%, respectively (Fig. 3B), indicating the efficacy of the two-dose vaccine
216 for the Delta variant as well.

217

218 **Neutralizing activities of the sera collected in December 2021 against the Delta and Omicron** 219 **variants**

220 We next analyzed the neutralization positivity rate against the Delta and Omicron variants in all
221 1,000 sera of the December 2021 cohort. The neutralization positivity rate against the Delta variant
222 was 78.7% (787/1,000) in the December 2021 cohort, indicating effective social immunity (Fig. 4A,
223 Table 3). In contrast, the neutralization positivity rate against the Omicron variant was quite low at
224 36.6% (366/1,000) (Fig. 4A, Table 3), implying the vulnerability of the cohort against infection by
225 the Omicron variant.

226 A further analysis of the same data with a separation of age groups revealed that the
227 neutralization positivity rate against the Delta variant tended to be lower in older age groups (Fig. 4B,
228 Table 3). The same trend was also observed in the neutralization positivity rate against the Omicron
229 variant (Fig. 4B, Table 3), and in the oldest age group (70–79 yrs) only 15.0% of the sera
230 demonstrated the neutralization activity.

231 The comparison of the anti-S antibody titers between the neutralization-positive and -negative
232 sera revealed that the neutralization-positive group had clearly higher titers of anti-S antibody in both
233 the Delta and Omicron cases (Fig. 4C), supporting our speculation that the neutralization activity of
234 the sera was attributed to the anti-S antibodies.

235 Lastly, we focused on the anti-N-positive (n=39) and anti-S positive (n=908) subsets of the
236 December 2021 cohort. The neutralization-positive rate against the Delta and the Omicron variants
237 for the anti-N positive subset were 89.7% and 59.0%, respectively (Fig. 4D). These values were
238 slightly higher than those for the entire set of 1,000 sera or those for the anti-N negative subset
239 (78.3% and 35.7% for the Delta and the Omicron variants, respectively), indicating superior immune

240 responses in the individuals with a history of SARS-CoV-2 infection. The neutralization positive rate
241 for the anti-S positive subset were 86.2% and 40.3% against the Delta and the Omicron variants,
242 respectively.

243

244 **DISCUSSION**

245 In combination with other methods used to understanding the spread of infectious diseases such
246 as the polymerase chain reaction (PCR)-based diagnosis and antigen tests, periodic cross-sectional
247 seroepidemiologic surveillance is a powerful approach. Our present surveillance in Japan's Hyogo
248 prefecture revealed that the anti-N-positive rate, which represents the SARS-CoV-2 infection rate, was
249 2.1% in the August 2021 cohort and 3.9% in the December 2021 cohort. In our October 2020
250 serosurveillance [20], the anti-N-positive rate by the same ECLIA method for 1,000 sera from the same
251 Hyogo Prefecture Health Promotion Association clinics was 0.4%. The increase in the anti-N-positive
252 rate in Hyogo prefecture was well synchronized with the cumulative number of the COVID-19 cases
253 based on PCR results (Fig. 5). The increased rate of anti-N seroprevalence was 0.17% per month from
254 October 2020 to August 2021 and 0.45% per month from August 2021 to December 2021. The steep
255 increase during the latter period is accounted for by the spread of the Delta variant in Japan's so-called
256 '5th wave' (Suppl. Fig. S1).

257 We suspected that the SARS-CoV-2 infection rate estimated by the seroprevalence of anti-N
258 antibody would be higher than the rate indicated by the PCR-based diagnoses due to the existence of
259 asymptotically or mildly infected individuals whose cases may not have been detected since they
260 never underwent testing by PCR analysis or antigen test. Indeed, the anti-N ECLIA-based infection
261 rates revealed in the present analyses, i.e., 2.1% and 3.9% for August and December 2021, were
262 respectively higher than the rates 0.85% (45,789 cases/5.4 million people in Hyogo prefecture as of
263 August 6, 2021) and 1.5% (78,718 cases/5.4 million people in Hyogo prefecture as of December 8,
264 2021) estimated from the reported cases based on PCR diagnoses [1]. The fold difference was nearly

265 constant for both periods, reflecting the synchronized increases in the anti-N-positive rate and the
266 reported cases (Fig. 5), i.e., 2.5- to 2.6-fold lower for the PCR-based estimation.

267 Even if we compensate for the biased age distribution in our cohorts (which were composed
268 mainly of 20- to 80-year-olds), it is likely that the PCR-based infection rates are approx. 2-fold lower
269 than the infection rate revealed by our serosurveillance, given the matched population 4.1 million for
270 20- to 80-year-olds and the finding that no less than 80% of COVID-19 cases in Japan are among 20- to
271 80-year-olds [25]. This is consistent with the report that a substantial portion of SARS-CoV-2-infected
272 individuals are asymptomatic [26], leading to the inaccuracy of surveillance rates determined solely by
273 PCR diagnosis.

274 Two-dose COVID-19 vaccination has been intensively promoted in Japan from May to
275 December 2021, and approx. 74% population has finished the two-dose vaccination (as of January 6,
276 2022; [12]). This is a relatively high rate considering the global average (46%) in January 2022
277 (January 6, 2022; [27]). Our anti-S seroprevalence result for the August 2021 cohort (38.7%)
278 represents the build-up period of social immunity (Table 2, Fig. 1A), and it is well consistent with
279 Hyogo prefecture's single and two-dose vaccination rates at 32.79% and 42.05%, respectively as of
280 August 6, 2021. In December 2021, when the vaccination rate had reached a plateau in Japan, our
281 survey revealed an extremely high seropositive rate, i.e., 90.8% (Table 2, Fig. 1B). This result
282 indicates that the vaccinations in Japan (*i*) have established herd immunity, and (*ii*) may have
283 contributed to the current COVID-19 situation having calmed down in December 2021 (Suppl. Fig.
284 S1, Fig. 5).

285 The anti-S seroprevalence observed in the present study is clearly higher compared to the
286 reported single- and two-dose vaccination rates in Hyogo prefecture as of December 8, 2021 at
287 73.09% and 74.01%, respectively. This difference might be accounted for by the bias in age groups of
288 the present cohorts which contained very few people <20 years old, whose vaccination rate has been
289 relatively low compared to those of other age groups [28]. In addition, our cohorts consisted of

290 individuals who underwent a health check-up, and this could have contributed to a biased selection of
291 socially active and health-conscious people.

292 Our comparison of the anti-N and anti-S seropositive rates among the age groups revealed
293 differing tendencies between the August 2021 and December 2021 cohorts (Fig. 1A,B). The August
294 2021 cohort—which was enrolled during a period of vaccination progression and the beginning
295 of the Delta variant's rampage—represents competing effects of the vaccinations and the Delta
296 variant. The high anti-S-positive rate for the age groups 60–69 and 70–83 years observed herein is
297 explained by the priority vaccination for elderly individuals (>65 yrs) in Japan (Fig. 1A). Interestingly,
298 the high anti-S-positive rate might be related to the relatively low infection rate (low anti-N-positive
299 rate) in the present study's elderly age groups (Fig. 1A), indicating the vaccines' efficacy.

300 In contrast, the December 2021 cohort was enrolled during the period in which the 'fully
301 vaccinated' rate had reached a plateau and the increase in the number of COVID-19 cases due to the
302 Delta variant had dropped to a low level (Suppl. Fig. S1). The anti-N-positive rate was increased in
303 the 20–29 and 70–79 age groups in this cohort (Fig. 1B). Although the anti-S-positive rate of the
304 December 2021 cohort showed no apparent difference among age groups (Fig. 1B), our quantitative
305 analysis of the anti-S antibody titers suggested that the increased infection for the 70- to 79-year-olds
306 was the result of the decreased anti-S antibody titers for the elderly age groups (Fig. 2B). Indeed, the
307 anti-S antibody level was significantly lower for the December 2021 cohort compared to that for the
308 August 2021 cohort (Fig. 2A), reflecting the decline of acquired immunity after vaccination.

309 Regarding the increase in the positive rate of anti-N antibody in the 20–29 age group, we speculate
310 that this increase might reflect increased social activity among these younger individuals.

311 As shown in Figure 4A, the neutralization assay using the SARS-CoV-2 viruses revealed that
312 the December 2021 cohort had a high neutralization-positive rate for the Delta variant, i.e., 78.7%.
313 This result demonstrated the two-dose vaccination suppressed the spread of the Delta variant, leading
314 to a transient convergence of the COVID-19, resulting in the relatively low infection rate of 3.9%.

315 The emergence of the Omicron variant is a key event worldwide, as is the subsequent spread of
316 the Delta variant. As of December 2021, European countries and U.S. have been invaded by the
317 Omicron variant, which has also been detected across Japan. Our neutralization assay against the
318 Omicron variant for the December 2021 cohort, which represents the current Japanese vaccinated
319 population, demonstrated a quite low positive rate, 36.6% (Fig. 4A) which appears to be due at least
320 in part to several mutations that occurred in the S protein [29-31]. We thus contend that the
321 three-dose vaccination to boost the immunity against Omicron is needed to prevent and suppress the
322 further spread of the Omicron variant. Our present findings also demonstrate the efficacy of vaccines
323 for SARS-CoV-2 suppression. The booster should be required, in order to increase the population's
324 immunity to the novel variant Omicron.

325

326 **Funding:**

327 This work was supported by the Hyogo Prefectural Government.

328

329 **Conflict of Interest:**

330 The authors declare no conflict of interest in this research.

331

332 **Acknowledgments:**

333 We thank Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural Hospital Agency and
334 Professor, Kobe University) for his full support of this study. We express our sincere gratitude for the
335 cooperation and participation of the staff of the Hyogo Prefecture Health Promotion Association. We
336 also thank researchers of the Division of Respiratory Medicine, Department of Internal Medicine,
337 Kobe University Graduate School of Medicine. We thank BIKEN Innovative Vaccine Research
338 Alliance Laboratories for providing the SARS-CoV-2 B2 strain used herein as the D614G variant. We
339 also thank the National Institute of Infectious Disease Japan for providing the SARS-CoV-2 B.1.167.2

340 variant and the B.1.1.529 variant used as the Delta variant and the Omicron variant, respectively. YK
341 was supported by the Taniguchi Memorial Scholarship program provided by the BIKEN Foundation.
342 SS and LHT were supported by Japanese Government (Monbukagakusho: MEXT) Scholarships.

343

344 **Contributions:**

345 ZR contributed to all of the experiments and analyses of the data. ZR, LHT, KF, YK, and SS performed
346 the neutralization assay. MN, KF, JA and YM supported the maintenance of the Biosafety Level 3
347 laboratory. ZR, LHT, KA, and NH performed the S ELISA measurement. KU, KM, IS, and JS
348 performed the N ECLIA measurement. NG, KT, and MY performed the large-scale protein expression
349 and purification of the Spike antigen for the S ELISA measurement. TN collected the sera and managed
350 their attributed data. YM conducted and supervised the study. ZR, LHT, FK, MN, JA, and YM
351 summarized the entire data set. The draft of the manuscript was written by ZR, LHT, MN, and YM. All
352 authors approved the final version of the manuscript.

353

354 **References:**

355

- 356 1. Trend in the number of newly confirmed cases (daily) in Japan. Available at:
357 https://covid19.mhlw.go.jp/public/opendata/confirmed_cases_cumulative_daily.csv.
358 Accessed 6 January.
- 359 2. Murayama H, Kayano T, Nishiura H. Estimating COVID-19 cases infected with the
360 variant alpha (VOC 202012/01): an analysis of screening data in Tokyo, January-March
361 2021. *Theor Biol Med Model* 2021; 18(1): 13.
- 362 3. Ito K, Piantham C, Nishiura H. Predicted dominance of variant Delta of SARS-CoV-2
363 before Tokyo Olympic Games, Japan, July 2021. *Euro Surveill* 2021; 26(27).
- 364 4. Omicron variant: what you need to know. Available at:
365 <https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html>. Accessed
366 December 15.
- 367 5. COVID-19 Weekly Epidemiological Update Edition 70, published 14 December 2021.
368 Available at:
369 <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20211214-weekly-epi-update-70.pdf>. Accessed 13 January 2022.
- 370 6. COVID-19: Omicron daily overview. Available at:
371 <https://www.gov.uk/government/publications/covid-19-omicron-daily-overview>.
372 Accessed December 31.
- 373 7. COVID Data Tracker. Available at:
374 https://covid.cdc.gov/covid-data-tracker/#trends_dailycases. Accessed January 10.
- 375 8. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and
376 Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and
377 mortality in older adults in England: test negative case-control study. *BMJ* 2021; 373:
378 n1088.
- 379 9. Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and
380 vaccine candidates. *Clin Immunol* 2021; 222: 108634.
- 381 10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
382 Covid-19 Vaccine. *N Engl J Med* 2020; 383(27): 2603-15.
- 383 11. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273
384 SARS-CoV-2 Vaccine. *N Engl J Med* 2021; 384(5): 403-16.
- 385 12. Open data of vaccination in Japan. Available at: https://cio.go.jp/c19vaccine_dashboard.
386 Accessed 6 January.
- 387 13. COVID-19 Vaccine Booster Shots (3rd Dose). Available at:
388 <https://www.mhlw.go.jp/stf/covid-19/booster.html>. Accessed 6 January.
- 389 14. Zurcher K, Mugglin C, Suter-Riniker F, et al. Seroprevalence of SARS-CoV-2 in
390 healthcare workers from outpatient facilities and retirement or nursing homes in a
391 Swiss canton. *Swiss Med Wkly* 2021; 151(33-34).
- 392 15. Santosh CS, Tukaram DP, Maharudra K, et al. Seroprevalence of SARS-CoV-2
393 Antibodies and Associated Factors in Health Care Workers. *J Assoc Physicians India*
394 2021; 69(8): 11-2.
- 395 16. Batool H, Chughtai O, Khan MD, Chughtai AS, Ashraf S, Khan MJ. Seroprevalence of
396 COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional
397 study assessing exposure to COVID-19 and identification of high-risk subgroups. *BMJ*
398 *Open* 2021; 11(8): e046276.
- 399 17. Smigelskas K, Petrikonis K, Kasiulevicius V, et al. SARS-CoV-2 Seroprevalence in
400 Lithuania: Results of National Population Survey. *Acta Med Litu* 2021; 28(1): 48-58.
- 401 18. Naesens R, Mertens H, Clukers J, et al. SARS-CoV-2 seroprevalence survey among health
402 care providers in a Belgian public multiple-site hospital. *Epidemiol Infect* 2021; 149:
403 e172.
404

- 405 **19. Tjan LH, Nagano T, Furukawa K, et al. The Neutralizing Antibody Response against**
406 **Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine**
407 **Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity:**
408 **Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients. JMA J**
409 **2021; 4(1): 1-7.**
- 410 **20. Furukawa K, Arii J, Nishimura M, et al. Seroepidemiological Survey of the Antibody for**
411 **Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at**
412 **Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan. JMA J 2021; 4(1): 41-9.**
- 413 **21. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2**
414 **seroconversion in humans. Nat Med 2020; 26(7): 1033-6.**
- 415 **22. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.**
416 **Nature 2021; 591(7851): 639-44.**
- 417 **23. Furukawa K, Tjan LH, Sutandhio S, et al. Cross-Neutralizing Activity Against**
418 **SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic**
419 **in Japan. Open Forum Infect Dis 2021; 8(10): ofab430.**
- 420 **24. Egger M, Bundschuh C, Wiesinger K, et al. Comparison of the Elecsys(R)**
421 **Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for**
422 **the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta 2020; 509:**
423 **18-21.**
- 424 **25. Visualizing the data: information on COVID-19 infections. Available at:**
425 **<https://covid19.mhlw.go.jp/extensions/public/en/index.html>. Accessed 6 January.**
- 426 **26. Alene M, Yismaw L, Assemie MA, et al. Magnitude of asymptomatic COVID-19 cases**
427 **throughout the course of infection: A systematic review and meta-analysis. PLoS One**
428 **2021; 16(3): e0249090.**
- 429 **27. WHO Coronavirus (COVID-19) Dashboard. Available at: <https://covid19.who.int/table>.**
430 **Accessed 6 January.**
- 431 **28. Vaccination rate by age in Hyogo prefecture, Japan. Available at:**
432 **<https://web.pref.hyogo.lg.jp/kf16/coronavaccine.html#wakuchinsessyujyoukyou>.**
433 **Accessed 13 January.**
- 434 **29. Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in**
435 **South Africa. J Med Virol 2021.**
- 436 **30. Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron**
437 **Variant of SARS-CoV-2. Nature 2021.**
- 438 **31. Dejnirattisai W, Huo J, Zhou D, et al. Omicron-B.1.1.529 leads to widespread escape**
439 **from neutralizing antibody responses. bioRxiv 2021.**
- 440

443 **Table 1.** Demographic information of the cohorts for the large-scale seroepidemiologic surveillance

	August 2021			December 2021		
	All	Male	Female	All	Male	Female
n (%)	1,000 (100%)	587 (58.7%)	413 (41.3%)	1000 (100%)	508 (50.8%)	492 (49.2%)
Age, yrs, median, (range)	48 (19–83)	51 (20–83)	44 (19–78)	49 (18-79)	42a (19-79)	49 (18-75)
Age groups, yrs, n:						
18-19*	4	0	4	3	2	1
20–29	123	41	82	104	48	56
30–39	179	97	82	149	85	64
40–49	243	134	109	257	123	134
50–59	236	153	83	265	123	142
60–69	174	133	41	182	99	83
70–83 [†]	41	29	12	40	28	12

444 * The August 2021 cohort contains only 19 years old in this age group

445 † The December 2021 cohort contains up to 79 years old in this age group

446 **Table 2.** Numbers of anti-N- and anti-S-positive samples by age groups

	August 2021			December 2021		
	All (n=1,000)	Male (n=587)	Female (n=413)	All (n=1,000)	Male (n=508)	Female (n=492)
SARS-CoV-2 anti-N antibody (ECLIA)						
Positive no. by age group, yrs, n						
18-19*	0	0	0	0	0	0
20-29	1	0	1	11	6	5
30-39	6	5	1	5	5	0
40-49	10	7	3	12	6	6
50-59	3	3	0	6	5	1
60-69	1	1	0	3	1	2
70-83†	0	0	0	2	1	1
Positive no. in all subjects, n (%)	21 (2.1%)	16 (2.7%)	5 (1.2%)	39 (3.9%)	24 (4.7%)	15 (3.0%)
SARS-CoV-2 anti-S antibody (ELISA)						
Positive no. by age group, yrs, n						
18-19*	1	0	1	3	2	1
20-29	23	4	19	92	43	49
30-39	56	30	26	130	74	56
40-49	67	28	39	233	110	123
50-59	80	48	32	238	107	131
60-69	123	92	31	175	95	78
70-83†	37	26	11	37	26	11
Positive no. in all subjects, n (%)	387 (38.7%)	228 (38.8%)	159 (38.5%)	908 (90.8%)	457 (90.0%)	449 (91.3%)

447 * The August 2021 cohort contains only 19 years old in this age group

448 † The December 2021 cohort contains up to 79 years old in this age group

449 **Table 3.** Neutralization positive rate of the sera collected on December 2021

	Neutralization positive number, (%)	
	Delta	Omicron
by age groups, yrs,		
18-19 (n=3)	3 (100%)	3 (100%)
20-29 (n=104)	86 (82.7%)	59 (56.7%)
30-39 (n=149)	120 (80.5%)	62 (41.6%)
40-49 (n=257)	216 (84.0%)	104 (40.5%)
50-59 (n=265)	209 (78.9%)	91 (34.3%)
60-69 (n=182)	132 (72.5%)	41 (22.5%)
70-79 (n=40)	21 (52.5%)	6 (15.0%)
in all subjects (n=1,000)	787 (78.7%)	366 (36.6%)

450

451 **Figure legends**

452 **Fig. 1.** The anti-N and anti-S antibody seroprevalence of the August 2021 and the December
453 2021 cohorts. **A:** *Left panel:* The age distribution of the August 2021 cohort divided into six
454 age groups: 18–19, 20–29, 30–39, 40–49, 50–59, 60–69, and 70–83 years. *Middle panels:* The
455 anti-N-positive rate and (*right panels*) anti-S-positive rate by the age groups. **B:** The age
456 distribution of the December 2021 cohort: 19, 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79
457 years.

458

459 **Fig. 2.** Quantitative evaluation of the anti-S antibody amount by the anti-S ELISA. **A:** The
460 distributions of the anti-S ELISA AUC values were compared between the August 2021 and
461 December 2021 cohorts. *P*-value, Mann-Whitney U-test. *Black bars:* medians. **B:** The
462 distributions in panel A plotted separately for the age groups. The Kruskal-Wallis test was
463 performed for the multiple comparison among age groups in the August and December cohorts.
464 The *P*-values were obtained by the subsequent Dunn's multiple comparison test for significant
465 data (<0.05). *Black bars:* medians.

466

467 **Fig. 3. A:** Neutralization antibody titers of the anti-S-positive subset of the August 2021 cohort
468 plotted for D614G and the Delta variant. *Black bars:* medians. *P*-value, Mann-Whitney U-test.

469 **B:** The neutralization-positive rates for D614G and the Delta variant were evaluated from the
470 data shown in panel A, with the titers <2 deemed negative.

471

472 **Fig. 4.** Neutralization activity of the sera collected in December 2021 against the Delta and
473 Omicron variants. **A:** The neutralization-positive rates of the entire December 2021 cohort
474 (n=1,000) plotted for the Delta and Omicron variants. **B:** The neutralization-positive rates for
475 the Delta and Omicron variants by age groups. The data in panel A were reanalyzed as in Fig.
476 2B. **C:** Comparison of the anti-S antibody amount between the neutralization-positive and
477 -negative groups. The complete set of 1,000 sera of the December 2021 cohort were
478 subgrouped according to result of the neutralization assay against the Delta variant and the
479 Omicron variant, and the anti-S antibody titers were plotted. *P*-value, Mann-Whitney U-test.
480 *Black bars:* medians. **D:** The neutralization-positive rate calculated for the anti-N-positive
481 (n=39) and anti-S (n=908) subsets obtained by extracting the data from those shown in panel
482 A.


483

484 **Fig. 5.** The COVID-19 situation in Hyogo prefecture, Japan. The cumulative infection cases
485 reported based on the PCR diagnosis [1] are plotted as the *solid line*, and the infection rates
486 obtained by our serosurveillance surveys are plotted as the *dashed line*. The anti-N-positive



487 rate shown by the ECLIA for the October 2020 cohort was obtained from our previous study
488 [20]. The rapid increase in the number of COVID-19 cases, i.e., the so-called 2nd to 5th
489 waves in Japan, are also indicated.

Figure 1


A



August 2021



B



December 2021





Figure 2





Figure 3








Figure 4**A****B****C****D**

Figure 5

COVID-19 in Hyogo prefecture, Japan

